​

bluebird bio (BLUE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BLUE Stock Forecast

bluebird bio (BLUE) stock forecast, based on 35 Wall Street analysts, predicts a 12-month average price target of $13.69, with a high of $25.00 and a low of $5.00. This represents a 230.68% increase from the last price of $4.14.

- $5 $10 $15 $20 $25 High: $25 Avg: $13.69 Low: $5 Last Closed Price: $4.14

BLUE Stock Rating

bluebird bio stock's rating consensus is Hold, based on 35 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (40.00%), 17 Hold (48.57%), 4 Sell (11.43%), and 0 Strong Sell (0.00%).

Hold
Total 35 0 4 17 14 Strong Sell Sell Hold Buy Strong Buy

BLUE Price Target Upside V Benchmarks

TypeNameUpside
Stockbluebird bio230.68%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$4.14$4.14$4.14
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 251-5--6
Mar, 251-6--7
Feb, 25116-210
Jan, 25116-210
Dec, 24116-210
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 22, 2022Gena WangBarclays$5.00$5.83-14.24%20.77%
Mar 07, 2022David NierengartenWedbush$6.48$2.88125.00%56.52%
Nov 19, 2021Cory KasimovJ.P. Morgan$14.00$10.7030.84%238.16%
Nov 12, 2021Zhiqiang ShuBerenberg Bank$11.00$11.68-5.82%165.70%
Nov 08, 2021Salveen RichterGoldman Sachs$10.00$10.70-6.54%141.55%
Sep 13, 2021Joshua SchimmerEvercore ISI$25.00$11.84111.15%503.86%
Aug 10, 2021John NewmanCanaccord Genuity$20.00$12.9754.20%383.09%
Aug 09, 2021Benjamin BurnettStifel Nicolaus$18.00$11.7653.06%334.78%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 31, 2024BarclaysOverweightOverweighthold
Sep 25, 2024Wells FargoSector PerformSector Performhold
Aug 15, 2024RBC CapitalSector PerformSector Performhold
Aug 15, 2024OppenheimerPerformPerformhold
Mar 27, 2024Wells FargoSector PerformSector Performhold
Dec 15, 2023Wells FargoEqual-WeightEqual-Weighthold
Jul 19, 2023WedbushNeutralBuyupgrade
Jun 01, 2023BarclaysEqual-WeightOverweightupgrade
Aug 22, 2022BarclaysEqual-Weightupgrade
Aug 22, 2022William BlairMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$-150 $-120 $-90 $-60 $-30 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-9.95$-8.16$-3.39$-1.93$-24.84----
Avg Forecast$-6.42$-11.60$-84.10$-35.43$-21.33$-8.09$-2.35$-6.63$-0.78
High Forecast$-3.61$-6.53$-49.86$-19.90$-19.04$-2.95$-1.15$-3.24$-0.38
Low Forecast$-9.52$-17.21$-121.93$-44.98$-22.92$-16.57$-3.63$-10.21$-1.20
Surprise %54.98%-29.66%-95.97%-94.55%16.46%----

Revenue Forecast

$0 $140M $280M $420M $560M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$250.73M$3.66M$3.60M$29.50M$83.81M----
Avg Forecast$259.09M$47.99M$4.34M$39.90M$72.04M$244.87M$353.18M$350.75M$485.05M
High Forecast$355.42M$65.84M$5.84M$44.02M$73.67M$306.51M$500.40M$496.95M$687.23M
Low Forecast$172.01M$31.86M$2.98M$34.41M$70.76M$154.66M$214.24M$212.77M$294.23M
Surprise %-3.23%-92.37%-17.11%-26.07%16.34%----

Net Income Forecast

$-3B $-2B $-2B $-1B $-600M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-618.70M$-562.64M$-266.58M$-211.91M$-240.72M----
Avg Forecast$-650.26M$-1.27B$-469.62M$-91.17M$-2.30B$-1.07B$-262.32M$-738.67M$-85.66M
High Forecast$-520.20M$-717.43M$-375.69M$-72.93M$-2.09B$-323.80M$-126.24M$-355.49M$-41.85M
Low Forecast$-780.31M$-1.89B$-563.54M$-109.40M$-2.52B$-1.82B$-398.40M$-1.12B$-132.08M
Surprise %-4.85%-55.84%-43.24%132.44%-89.55%----

BLUE Forecast FAQ

Is bluebird bio stock a buy?

bluebird bio stock has a consensus rating of Hold, based on 35 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 17 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that bluebird bio is a neutral investment for most analysts.

What is bluebird bio's price target?

bluebird bio's price target, set by 35 Wall Street analysts, averages $13.69 over the next 12 months. The price target range spans from $5 at the low end to $25 at the high end, suggesting a potential 230.68% change from the previous closing price of $4.14.

How does bluebird bio stock forecast compare to its benchmarks?

bluebird bio's stock forecast shows a 230.68% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for bluebird bio over the past three months?

  • April 2025: 16.67% Strong Buy, 0% Buy, 83.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 14.29% Strong Buy, 0% Buy, 85.71% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 10.00% Strong Buy, 10.00% Buy, 60.00% Hold, 0% Sell, 20.00% Strong Sell.

What is bluebird bio’s EPS forecast?

bluebird bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-8.09, marking a -67.43% decrease from the reported $-24.84 in 2024. Estimates for the following years are $-2.35 in 2026, $-6.63 in 2027, and $-0.78 in 2028.

What is bluebird bio’s revenue forecast?

bluebird bio's average annual revenue forecast for its fiscal year ending in December 2025 is $244.87M, reflecting a 192.18% increase from the reported $83.81M in 2024. The forecast for 2026 is $353.18M, followed by $350.75M for 2027, and $485.05M for 2028.

What is bluebird bio’s net income forecast?

bluebird bio's net income forecast for the fiscal year ending in December 2025 stands at $-1.072B, representing an 345.18% increase from the reported $-241M in 2024. Projections indicate $-262M in 2026, $-739M in 2027, and $-85.664M in 2028.